

Advances in Precision Medicine: Nanotechnology, Gene Editing and Regenerative Engineering for Cancer and Rehabilitation

ABSTRACT

Advances in biomedical technology are transforming modern healthcare by enabling more precise, personalized, and accessible treatment strategies. This paper examines key innovations across nanotechnology, gene editing, prosthetics, and regenerative medicine, highlighting their collective impact on disease treatment and patient rehabilitation. Nanoparticle-based drug delivery systems improve chemotherapy by targeting cancer cells more selectively, reducing systemic toxicity and enhancing therapeutic outcomes. Similarly, CRISPR gene-editing technologies offer promising approaches to cancer treatment by modifying immune response and inhibiting tumor growth at the genetic level. In parallel, the development of 3D-Printed prosthetics and brain-computer interfaces has expanded possibilities for restoring motor function and improving quality of life. Additionally, stem cell bioprinting demonstrates significant potential in tissue regeneration. However, ethical concerns including gene editing risks, unequal access, and long-term safety, which all remain critical considerations alongside these advancements. In the course of stem cells in bioprinting, they must survive.


Introduction

The evolution of biomedical technology has been shaped by centuries of scientific discovery and innovation aimed at improving human health and longevity. Early medical advancements, such as the development of rudimentary prosthetics in ancient civilizations, demonstrated humanity's initial attempts to restore physical function. However it was not until the 20th Century that significant breakthroughs began to accelerate, particularly with the use of modern science/chemistry, imaging technologies, and molecular biology. The discovery of DNA's structure in the 1900s marked a turning point, laying the foundation for genetic engineering and, eventually, gene-editing tools such as CRISPR. Simultaneously, progress in materials, science, and engineering enabled the development of more sophisticated prosthetic devices and the emergence of medical robotics, improving surgical precision and patient outcomes. The late 20th and early 21st centuries saw the rise of nanotechnology, allowing scientists to manipulate matter

at the molecular level and opening new possibilities for targeted drug delivery and cancer treatment. In parallel, stem cell research introduced regenerative medicine as a promising field capable of repairing or replacing damaged tissues, while the ethical limitations were more recently addressed by James Thompson and John Gearhart in 1998 . More recently, innovations such as 3D printing and brain-computer interfaces have further expanded the boundaries of personalized medicine and rehabilitation. Despite the rapid advancements, the integration of such technologies into healthcare systems continues to raise important ethical, economic, and accessibility concerns.

Applications of Nanoparticle Drug Delivery for Targeted Chemotherapy

Chemotherapy is one of the main ways doctors fight cancer, but it has a huge problem: it is not very specific. It often kills healthy cells along with the bad ones, leading to drastically damaging side effects like hair loss and organ damage. Physical and chemical parameters by use of nanoparticles can transform drug delivery from systemic distribution to highly localized, targeted therapy (Zhang et al., 2017). The proof of “precision therapy” lies in the research highlighting that spherical gold nanoparticles earn a cellular reuptake of 2.75-5 times higher than their rod-shaped alternatives. The application of nanobiotechnology at the 10^{-9} meter scale is the key to achieving this form of therapy (Zhang et al., 2017). This is a revolutionary way to optimize the therapeutic index, delivering a maximal effect with minimal damage. **Normally, the blood-brain barrier (BBB) acts as a biological shield that blocks the majority of small-molecule drugs, but nanomedicine allows for non-invasive, targeted delivery across this barrier without altering the drug’s core characteristics (Jovčevska, 2022).** By using the EPR effect (Enhanced Permeability and Retention) where particles larger than 100 nm leak into and stay trapped within diseased tissue, these nanodrugs can bypass the body’s natural defenses. This results in higher intracellular concentrations, effectively overcoming multiple drug resistance (MDR) and providing a superior alternative to conventional treatments correlating to high toxicity and/or poor retention.(Jovčevska, 2022)



(Figure 1: Nanotechnology at the 10^{-9} meter scale works by targeting cancer cells more precisely than current popularized pharmaceuticals)

Interventions of CRISPR Gene Editing as Gene-Editing Tools for Cancer

Researchers argue that CRISPR is a very prominent form of genome-editing tool that can slow tumor growth in preclinical models. Specifically, editing genes in immune systems by analyzing the PD-1/immune checkpoint genes in T cells can boost their ability to recognize and kill certain cancer cells (Chelhelgerd et al., 2024). This was addressed in a Phase 1 Trial where PD-1 edited T-cells in advanced non-small cell lung cancer unraveled a median progression-free survival of 7.7 weeks, whereby preclinical trials highlighted how the CRISPR gene can lead to a significant reduction of tumor growth in cancer cells like lymphoma (Chelhelgerd et al., 2024). Furthermore, CRISPR gene editing has been shown to significantly reduce the expression of immune checkpoints and modulate tumor microenvironments as well as improve the persistence. Researchers argue that through CRISPR gene editing, researchers can inactivate specific genes that drive tumor growth; furthermore, combining CRISPR-based approaches with other cancer therapies can maximize efficacy and also improve treatment outcomes. Furthermore, another group of researchers assessed the effectiveness of CRISPR gene, and unraveled how the CRISPR-Cas9 targeting of the specific PD-1 gene was able to achieve a median of 87.5% reduction in cell surface, which was confirmed at the genomic level. Furthermore, they revealed that the targeted knock-in of the CAR into T-cell receptor was able to lead to enhanced tumor rejection as opposed to randomly integrated constructs (Wang et al., 2022). Currently, as research stands today, the development of safe in-vivo delivery remains to be one of the biggest challenges in the clinical use of CRISPR gene therapy, as there are prominent challenges in immunogenicity and cytotoxicity that need to be addressed.




Fig. 7 The structure of mixed TCR dimers and the application of CRISPR/Cas9 in TCR-T cell therapy. Introduction of transgenic TCRs can cause formation of new reactive TCR dimers. Knock-out of endogeneous TCRs avoids the formation of mixed TCR dimers and increases the expression of transduced TCRs


(Figure 1: Analysis of Applications of CRISPR/Cas9 in T-Cell Therapy)

Evaluation of 3D-Printed Prosthetics for Disabled Patients

Researchers argue that 3D printing has made significant advancements in helping patients with physical disabilities in the context of rehabilitation centers. The World Health Organization has estimated that two billion patients will need at least one assistive product by 2030, and this form of additive manufacturing could help meet this demand. One group of researchers unraveled that 3D printing was primarily used to develop assistive devices for patients with limb deficiencies, followed by lower-limb applications with a 58.25% for upper limbs and 31.25% for lower-limbs representation (Pereira et al., 2024). In terms of findings, one group of patients assessed creating 3D-printed finger prostheses that “mimicked distal interphalangeal joint motion” and after a 1 month completion of prosthesis training, both patients were able to show sustained and improved performance in patient-derived goals of cooking as well as typing on computer. Furthermore, there were other advantages to the clinical applications where the modeling of the prosthesis was performed easily by measuring only 9 parameters and the cost to produce these 3D-printed finger prosthesis was very low at approximately a cost of \$30, as opposed to commercial prosthetic fingers which can be more costly at around \$4,000 to \$10,000. Despite the limitations, these research results highlight the potential of body-powered 3D printed finger prostheses that have a high potential on top of existing cosmetic prostheses (Lee et al., 2022). Given prosthetics are very hard to access in low-income communities, as supported by the World Health Organization that solely 5-15% of patients in lower-income countries have access to prostheses, it is crucial to expand upon accessibility. When collecting results globally on the effectiveness of these tools for low-income patients, researchers discovered that body-powered 3D grid prosthetic hands proved to be effective for wrist disarticulation, and 3D-printed prosthetics that were body-powered were helpful for patients in Uganda (Abbady et al., 2022).

Analysis of Brain-Computer Interfaces (BCI) For Prosthetic Limb Control

Researchers have explored how brain-computer interfaces (BCIs) can improve motor rehabilitation for patients with severe paralysis, particularly those with tetraplegia caused by spinal cord injury. One study by Thomas (2019) demonstrated that pairing sensory stimulation with motor intent using a BCI system can enhance rehabilitation outcomes. This system detects movement intent through electroencephalography (EEG) and delivers real-time sensory feedback, creating a closed-loop system. Findings showed that sensory stimulation could be accurately timed to occur just before or during attempted movement, which aligns with optimal timing identified in paired associative stimulation (PAS) research. This suggests that integrating sensory feedback with voluntary effort may improve motor recovery more effectively than traditional open-loop methods (Thomas, 2018). Similarly, Baniqued (2022) investigated the integration of BCIs with virtual reality (VR) and robotic exoskeletons to enhance motor imagery training. The study found that adding enriched visual and kinaesthetic stimuli through VR environments and robotic hand devices significantly improved BCI performance. In particular, participants using VR-based training showed higher classification accuracy in interpreting brain signals, with statistically significant improvements ($p = 0.0422$). Additionally, most VR training sessions achieved class prediction probabilities above a functional threshold, indicating more reliable signal detection. These findings suggest that combining immersive technologies with BCIs can strengthen neural engagement and improve the effectiveness of rehabilitation systems. Together, these studies highlight the growing potential of BCI-based systems in neurorehabilitation. By incorporating real-time sensory feedback and immersive environments, researchers demonstrate that patients with motor impairments may achieve better functional outcomes. These advancements not only improve rehabilitation strategies but also point toward future applications in skill learning and assistive technologies, making therapy more interactive, adaptive, and accessible (Thomas, 2019; Baniqued, 2022).



Analysis of Bioprinting Stem Cells for Tissue Regeneration

Researchers demonstrated that 3D bioprinting is revolutionizing tissue engineering and regenerative medicine by overcoming the limitations of traditional scaffold-based methods (Murphy and Atala, 2014; Xionfa et al., 2018). While older techniques often result in random cell distribution and lack the complexity of native biological practices, 3D bioprinting uses an automated, top-down additive manufacturing approach to construct tissues layer-by-layer (**Bose et al., 2013**). This process is guided by anatomically accurate CAD/CAM models, allowing for precise geometries that mimic human physiology (Melchels et al., 2012). A critical component of this tech is bioink, a composite of living cells and biomaterials like alginate, collagen and PED, which ensures biocompatibility and supports cell differentiation. In bone tissue engineering, hydrogel bioink composition critically regulates stem cell behavior. Campos et al. (2016) developed 3D-bioprinted agarose–collagen type I hydrogels that improved mechanical stability and print fidelity compared to pure collagen, while maintaining a supportive environment for mesenchymal stem cells (MSCs). Achieving a balance between mechanical stiffness and biochemical signaling is essential to replicate extracellular matrix (ECM) conditions necessary for bone regeneration (**Ulrich et al., 2010; Huebsch et al., 2010**). The study showed that MSCs survived the bioprinting process and retained their mesenchymal phenotype, confirmed by live/dead staining and immunocytochemical markers (vimentin positive, CD34 negative) (**Campos et al., 2016**), addressing concerns regarding shear stress during extrusion (Blaeser et al., 2015). Moreover, higher collagen concentrations enhanced cell spreading and significantly increased mineralization, verified through Alizarin Red staining and gene expression analysis (Campos et al., 2016). These results highlight the importance of matrix composition and stiffness in directing osteogenic differentiation (**Khatiwala et al., 2007; Kumar et al., 2011**).

Ethics, Discussion, Limitations

Despite these technological implications of biomedical technologies, it is crucial to consider some of the ethical limitations, particularly associated with CRISPR gene editing, nanoparticle drug delivery, bioprinting as well as brain-computer interfaces (BCIs). Researchers argue that these CRISPR genes have been assessed for their heritability, and issues surrounding consent from future generations. This is arguably the case where issues such as immunogenicity, off-target mutations, and long-term safety can lead to these clinical limitations. Furthermore, it is crucial to consider some of the limitations associated with the high developmental costs, regulatory policies that govern these technologies as well as unequal global access. For instance, despite BCIs having a growing transformation for patients with cognitive

impairments, to reflect neural plasticity, this form of medical solution may not be readily accessible for all patients across the world, particularly for those from low-income nations. Particularly for 3D prosthetics and CRISPR gene, it is also essential for patients diagnosed with cancer to be provided informed consent as well as appropriate disclosure, at the time of treatment and afterwards. As patients may be influenced by factors like tumor heterogeneity and immune response, it becomes crucial for researchers to ensure the patients are informed of the pro's and con's of these treatment outcomes. Lastly, with all of these treatment interventions, most studies lack longitudinal data which becomes critical, particularly for gene editing, nanoparticle accumulation as well as implanted prosthetics. In order to ensure minimal complications and results that are optimized over time, empirical research studies that take form of longitudinal studies will be significant for future researchers.

Conclusion

As evident in the discussions surrounding nanoparticle drug delivery, CRISPR gene editing, 3D-printed prosthetics, BCI as well as stem cell bioprinting, these significant transformations in the field of healthcare are creating leading changes for cancer treatment and rehabilitation for patients with physical disabilities. For one, the nanoparticle-based drug delivery systems are able to optimize the impact of chemotherapy by enabling targeted treatment. Secondly, the bioprinting technologies have been able to secure greater biocompatibility and cell differentiation for cancer cells in enhancing the immune responses. Similarly, CRISPR gene editing introduces the possibility of addressing disease at its genetic root, which is crucial in enhancing immune responses. Furthermore, the innovations in 3D printing and prosthetics have arguably opened doors to accessible and greater quality of life for patients with physical disabilities. Even for patients with brain impairments, BCIs are able to improve motor rehabilitation for patients with severe paralysis. The combination of precision medicine and integrative healthcare systems are increasingly becoming tailored to each patient need in overall, improving the clinical outcomes, recovery, adaptation, as well as long-term patient care. For patients with cognitive and physical disabilities, as well as those diagnosed with cancer, the combination of nanoparticle drug delivery, CRISPR gene editing, prosthetics, BCIs and stem cell bioprinting all are shifting the future of healthcare, enabling researchers to continue diving into the scientific paradigm of research and development for more readily-available diagnostics and treatments for future patients in need.

References

Abbady, Hnady EMA, et al. "3D-printed prostheses in developing countries: A systematic review." *Prosthetics and orthotics international* 46.1 (2022): 19-30.

Agarwal, Swarnima, et al. "Current developments in 3D bioprinting for tissue and organ regeneration—a review." *Frontiers in Mechanical Engineering* 6 (2020): 589171.

Blaeser, Andreas, et al. "Controlling shear stress in 3D bioprinting is a key factor to balance printing resolution and stem cell integrity." *Advanced healthcare materials* 5.3 (2016): 326-333.

Chehelgerdi, Mohammad, et al. "Comprehensive review of CRISPR-based gene editing: mechanisms, challenges, and applications in cancer therapy." *Molecular cancer* 23.1 (2024): 9.

Duarte Campos, Daniela Filipa, et al. "Bioprinting organotypic hydrogels with improved mesenchymal stem cell remodeling and mineralization properties for bone tissue engineering." *Advanced healthcare materials* 5.11 (2016): 1336-1345.

Jovčevska, Ivana. "Biological nanodrugs for brain targeting." *Nanocarriers for Drug-Targeting Brain Tumors*. Elsevier, 2022. 797-820.

Lee, Min-Yong, et al. "Functional improvement by body-powered 3D-printed prosthesis in patients with finger amputation: Two case reports." *Medicine* 101.25 (2022): e29182.

Pereira, Juarez de Souza, et al. "3D-printed orthoses and prostheses for people with physical disability in rehabilitation centers: a scoping review." *BMC Musculoskeletal Disorders* 25.1 (2024): 783.

Thomas, Sarah Helen. "A Brain-computer Interface for Closed-loop Sensory Stimulation During Motor Training in Patients with Tetraplegia." (2018).

Wang, Si-Wei, et al. "Current applications and future perspective of CRISPR/Cas9 gene editing in cancer." *Molecular cancer* 21.1 (2022): 57.

Zhang, Jing, et al. "Effects of major parameters of nanoparticles on their physical and chemical properties and recent application of nanodrug delivery system in targeted chemotherapy." *International journal of nanomedicine* (2017): 8483-8493.